{"id":391493,"date":"2014-11-26T00:00:00","date_gmt":"2014-11-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/srepemhxx-biopharma-emerging-market-special-report-hepatitis-c-virus-in-brazil\/"},"modified":"2026-03-31T09:04:22","modified_gmt":"2026-03-31T09:04:22","slug":"srepemhxx-biopharma-emerging-market-special-report-hepatitis-c-virus-in-brazil","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/srepemhxx-biopharma-emerging-market-special-report-hepatitis-c-virus-in-brazil\/","title":{"rendered":"Emerging Market Special Report: Hepatitis C Virus in Brazil"},"content":{"rendered":"<p>Prevalence of the hepatitis C virus (HCV) in Brazil is estimated to be among the highest in the world; in addition, the country faces the challenge of treating a largely undiagnosed HCV-infected population. Chronic HCV infections are often asymptomatic for years, which is a key barrier to diagnosis and treatment. Further, the lack of timely treatment can increase the risk of severe liver complications such as cirrhosis and hepatocellular carcinoma. The primary goal of HCV treatment is to completely eliminate the virus from the patient\u2019s body and thereby reduce or halt the progression of liver disease. Currently, the standard of care for chronic HCV infections in Brazil is a lengthy treatment course of pegylated-interferon -alpha (peg-IFN-?; Roche\u2019s Pegasys or Merck\u2019s PegIntron) plus ribavirin (Roche\u2019s Copegus, Merck\u2019s Rebetol, generics) or telaprevir- (Johnson &#038; Johnson\u2019s Incivo)  or boceprevir- (Merck\u2019s Victrelis) based triple therapy. The imminent approval and launch of follow-on direct-acting agents (e.g., Gilead\u2019s sofosbuvir, Janssen\/Medivir\u2019s simeprevir, Bristol-Myers Squibb\u2019s daclatasvir) is set to trigger a major shift in the treatment paradigm with the introduction of interferon-free therapy in Brazil; this market change is poised to drive an increase in treatment rates in this key emerging market.<\/p>\n","protected":false},"template":"","class_list":["post-391493","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-geography-brazil","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391493\/revisions"}],"predecessor-version":[{"id":576986,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391493\/revisions\/576986"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}